Increased mortality risk in people with schizophrenia in Lithuania 2001–2020

Introduction

Schizophrenia is a severe and chronic psychiatric disorder with often poor long-term outcomes1. People with schizophrenia are reported to have an elevated risk of premature mortality and a 10 to 20-year shorter life expectancy compared to the general population2,3. A previous meta-analysis showed that schizophrenia was associated with an average of 14.5 years of potential life loss, with higher numbers for males (15.9 years) than for females (13.6 years)4. Despite progress in treatment, recent analysis indicate that the mortality gap is increasing over time, suggesting that people with schizophrenia are not benefiting from medical advances as much as the general population2,5,6.

A recent systematic review and meta-analysis showed significantly higher all-cause mortality among patients with schizophrenia compared to the general population (Risk ratio (RR) = 2.94; 95% CI 2.75–3.13). Higher mortality risk from cardiovascular diseases (RR = 2.09; 95% CI 1.76–2.47), infectious diseases (RR = 3.84; 95% CI 2.10–7.01), respiratory diseases (RR = 3.75; 95% CI 2.99–4.70), and endocrine diseases (RR = 3.80; 95% CI 1.75–8.26) was also observed7.

The World Health Organization has identified lifestyle and health factors that contribute to earlier mortality, including heavy smoking, physical inactivity, obesity, hyperglycaemia, high cholesterol levels, and hypertension8. Together, these risk factors are responsible for increasing global mortality by 42.1%, and patients with schizophrenia have a higher incidence of these factors9. Despite major concerns regarding suicide in patients with schizophrenia, the majority of deaths associated with psychotic disorders are primarily attributed to natural causes, such as cardiovascular disease, cancer, and respiratory diseases10,11. Only a few studies present data on the influence of specific risk factors on mortality. Beary et al. concluded that while there is limited data in this field, interventions targeting modifiable risk factors such as hypertension, physical activity, and smoking could potentially improve the lifespan of individuals with schizophrenia12. Health inequalities in people with schizophrenia are a serious public health problem that warrants urgent attention to optimise healthcare services and reduce preventable deaths in this population13. To close the mortality gap between people with schizophrenia and the general population, certain interventions are needed, such as monitoring and screening for cardiovascular diseases, promoting healthy lifestyle education, and providing early interventions for diagnosed physical illnesses7.

Conducted studies report a high heterogeneity of mortality risk among patients with schizophrenia. To contribute to the existing literature and to explore the patterns of mortality risk, we conducted a single-centre, retrospective study to assess mortality risk in people with schizophrenia compared to the general population during the study period from 2001 to 2020.

Materials and methods

Study design and data source

Cause-specific and all-cause mortality risk among patients with schizophrenia in Lithuania were assessed using retrospective cohort study design. The cohort included all male and female patients diagnosed with schizophrenia (ICD-10 code F20) admitted to the Vilnius Republican Psychiatric Hospital.

The Vilnius Republican Psychiatric Hospital, situated in the capital of the Vilnius region, is the largest specialised psychiatric hospital in the country, with approximately 5000 hospital admissions each year. The hospital database contains a wide range of information, including demographics, personal identification numbers, dates of admission and discharge, principal diagnoses, and any coexisting medical conditions.

A cohort of patients with schizophrenia was established for analysing different aspects of their health conditions. A total of 8985 patients were admitted to the Vilnius Psychiatric Hospital during the period from January 1, 1992, until December 31, 2017.

The study population was followed for dates of emigration and dates of death from the date of hospitalisation to December 31, 2020. Dates of death and emigration were obtained from the Central Population Register. Underlying causes of death were obtained from death certificates. For mortality risk analysis we selected only patients, who were alive at January 1, 2001. This restriction relates to the availability of the causes of death from the Causes of Death Register.

The final cohort included 7883 patients.

Statistical analysis

To assess cause-specific mortality risk in the study cohort, common causes of death were classified into 15 broad categories according to the ICD-10.

The standardised mortality ratios (SMRs) were calculated by dividing the observed number of deaths among patients with schizophrenia by the expected number of deaths, calculated using national rates. The expected number of deaths was calculated by multiplying the exact person-years under observation in the cohort by sex, calendar year, and 5-year age-group specific national mortality rate. The person-time of observation was computed from January 1, 2001, or the date of the first hospitalisation with a schizophrenia diagnosis until the cohort exit date. Exact 95% confidence intervals (CIs) for standardised mortality ratios (SMRs) are calculated directly from the Poisson distribution using the R statistical package (R Core Team. 2024. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).

All statistical analyses were carried out using STATA 15 statistical software (StataCorp. 2020. Stata Statistical Software: Release 15.1. College Station, TX, USA).

The study was conducted in accordance with the Declaration of Helsinki, and the Vilnius Regional Biomedical Research Ethics Committee (No. 2022/6-1449-915) approved the protocol.

Results

The study population’s baseline characteristics are described in Table 1. The number of males and females in the study group was similar, comprising 50.5% and 49.5%, respectively. Additionally, 18.9% of males and 34.5% of females were first hospitalised at the age of 50 years or more.

Table 1 Characteristics of the study population.
Full size table

In total, 2458 deaths were observed in our study: 50.8% in the male group and 49.2% in the female group. An increased all-cause mortality risk was found for both male (SMR = 1.66; 95% CI 1.57–1.75) and female (SMR = 2.40; 95% CI 2.27–2.54) patients with schizophrenia combined (SMR = 1.96; 95% CI 1.88–2.04) compared to the general population.

The observed and expected numbers and the SMRs for the specific cause of death by sex are shown in Table 2. The absolute majority of death cases were due to natural causes. The most significant increase in natural cause-specific mortality risk was observed in both sexes for circulatory system diseases (47.7% of all cases with SMR = 2.17; 95% CI 2.05–2.30). Further subdivision of circulatory system diseases showed that deaths from ischaemic heart disease and cerebrovascular disease were significant in both sexes separately and combined. Statistically significant results for increased cause-specific mortality risk were observed in several diseases. These include infectious diseases (SMR = 2.34; 95% CI 1.81–2.98), mental and behavioural disorders (SMR = 10.72; 95% CI 7.76–14.44), diseases of the nervous system (SMR = 1.75; 95% CI 1.22–2.43), diseases of the respiratory system (SMR = 2.01; 95% CI 1.61–2.48), and disease of the genitourinary system (SMR = 2.46; 95% CI 1.52–3.76). Increased mortality risk due to cancer (SMR = 1.25; 95% CI 1.06–1.46), endocrine and metabolic diseases (SMR = 2.35; 95% CI 1.37–3.76), and digestive system diseases (SMR = 1.39; 95% CI 1.01–1.87) was observed only in female patients with schizophrenia, but not in males. In terms of unnatural causes of death, our results show that both genders died statistically significantly more (SMR = 2.70; 95% CI 2.47–2.95) than the general population.

Table 2 Standardised mortality ratios (SMR) for causes of death in patients with schizophrenia according to sex.
Full size table

Discussion

As mortality is considered one of the most important measures in medicine to monitor the quality of psychiatric and somatic healthcare14, we performed, to our knowledge, the first and largest study on all-cause and disease-specific mortality in people with schizophrenia in Lithuania. These results confirm previous findings that people with schizophrenia have a higher mortality rate than the general population, and the increase in mortality risk is due to almost all the diseases that are the leading causes of death in the general population.

The most recent meta-analysis, which included 135 studies comparing 4.5 million patients with schizophrenia, reported significantly increased all-cause mortality in people with schizophrenia compared to the general population (RR = 2.94, 95% CI 2.75–3.13)7. In terms of sex analysis, British and Norwegian studies found that males were characterised by higher mortality than females compared to the general population15,16. In our study, we also found increased all-cause mortality in people with schizophrenia combined compared to the general population (SMR = 1.96; 95% CI 1.88–2.04); however, females with schizophrenia had a higher SMR = 2.40 (95% CI 2.27–2.54) than males with schizophrenia (SMR = 1.66; 95% CI 1.57–1.75).

Most deaths in patients with schizophrenia are attributable to natural causes. A previous meta-analysis found that 67.3% of deaths among people with mental disorders were due to natural causes17. As mentioned before, higher mortality from cardiovascular diseases (RR = 2.09; 95% CI 1.76–2.47), infectious diseases (RR = 3.84; 95% CI 2.10–7.01), respiratory diseases (RR = 3.75; 95% CI 2.99–4.70) and endocrine diseases (RR = 3.80; 95% CI 1.75–8.26) was observed7. We observed the most significant increase in cause-specific mortality risk associated with circulatory system diseases (SMR = 2.17; 95% CI 2.05–2.30). Further subdivision of circulatory system diseases showed that deaths from ischaemic heart disease and cerebrovascular disease were significant in both sexes, separately and combined. According to a large meta-analysis that processed data from over 3 million patients, those with severe mental illness had a 53% higher risk of suffering from cardiovascular disease, a 78% higher risk of developing cardiovascular disease, and an 85% higher risk of dying from cardiovascular disease compared to the general population18. In Sweden, male and female patients with schizophrenia died from ischemic heart disease 14.5 and 12.7 years earlier than individuals in the general population19. Moreover, people with schizophrenia who died from myocardial infarction were less often diagnosed with ischemic heart disease compared to people who died from the same cause in the general population19. Interestingly, mortality due to cardiovascular disease in patients with schizophrenia did not decrease over the past few years, despite the fact that decreasing mortality rates from cardiovascular disease have been reported worldwide20.

The second most common cause of mortality in our study is due to cancer-related deaths. We found a statistically significant increase in mortality risk for female patients with schizophrenia (SMR = 1.25; 95% CI 1.06–1.46). In contrast, male patients showed no significant increase in mortality risk (SMR = 0.84; 95% CI 0.70–0.99), and the results for both genders do not show a statistically significant difference compared to the general population. In our previous study, we found a higher breast cancer mortality risk among female patients (SMR = 1.90; 95% CI 1.44–2.51), which could partially explain the higher overall cancer-related mortality risk among females with schizophrenia. Moreover, in the same study, we did not find any statistically significant differences in lung and colorectal cancer mortality in both males and females21. However, research findings on the relationship between schizophrenia and cancer mortality risk are very diverse. The latest meta-analysis on cancer mortality showed that the SMR for cancer mortality in patients with schizophrenia compared to the general population was 1.40 (95% CI 1.29–1.52), with statistically significant results in both female and male subgroups22. Stigmatisation of schizophrenia diagnosis, present among healthcare specialists, may limit patients’ access to healthcare10. Interestingly, the aforementioned Swedish study reported that malignant neoplasms were less often diagnosed in schizophrenia patients dying from cancer compared to those dying from the same cause in the general population19.

Other natural causes that have been shown to have an increased mortality risk in research studies of patients with schizophrenia are diabetes and infectious diseases. Brown et al. demonstrated a statistically significant higher SMR for diabetes in schizophrenia patients14. Our results on diabetes show an increased mortality risk for females (SMR = 2.14; 95% CI 1.17–3.59); however, this risk was not observed for males. A recent observational longitudinal study, which aimed to analyse mortality risk in people with schizophrenia with comorbid illness (type II diabetes), revealed that mortality was three times higher in the subgroup of patients with schizophrenia with type II diabetes compared to those who did not have any of the studied diseases. After adjustment for age, the risk of death in those with type II diabetes and schizophrenia increased to a 27-fold greater risk compared to those without either condition23. A recent meta-analysis found that patients with schizophrenia had approximately a 3-fold increased risk of hepatitis C and B compared to the general population, and authors discussed that this could be explained by certain behavioural factors: substance use and extreme sexual behaviours24. Our results indicate that, although the observed number of cases of viral hepatitis is low (overall 7), there is an increased overall mortality risk for both genders (SMR = 6.68).

In our study, increased mortality risk from mental and behavioural disorders was observed (SMR = 10.72). Similar to our study, Italian researchers reported a higher risk of deaths from psychiatric disorders (ICD-10 F00–F99) in both males (SMR = 13.2; 95% CI 10.5–16.2) and females (SMR = 6.8; 95% CI 5.3–8.6)25.

An increasing number of studies emphasise the importance of modifiable risk factors in reducing mortality risk, such as poor lifestyle behaviours, comorbid illnesses, and irregular use of antipsychotic drugs2. Patients are encouraged to monitor their weight, diet, exercise programs, and use of antipsychotics26. One study showed reduced cardiorespiratory fitness in people with schizophrenia compared to the general population, and the authors concluded that promoting physical activity might reduce overall and cardiovascular-associated mortality27. In addition, there is a shortage of advice on lifestyle changes, such as smoking cessation, which is particularly important, given that there is an 70–162% increased risk of chronic obstructive pulmonary disease, asthma, and pneumonia in patients with schizophrenia28. The association of schizophrenia and smoking has long been recognised29. Brown et al. analysed smoking habits in patients with schizophrenia and found that not only were there more smokers among people with schizophrenia (73%) than in the general population (35%), but the SMR was also significantly higher in smokers (SMR = 2.79) than in non-smokers (SMR = 1.94)14.

Although antipsychotics are associated with adverse cardiometabolic effects that can increase the risk of cardiovascular death30, it has been observed that there is a protective role of antipsychotic use in people with schizophrenia treatment compared to non-use31. Taipale et al. reported that antipsychotic medication use was not associated with an increased risk of hospitalisation due to cardiovascular disorders; in fact, they found a significantly decreased risk of dying from cardiovascular illness in people with schizophrenia who regularly used antipsychotics (HR = 0.62, 95% CI 0.57–0.67)31. Additionally, patients who used antipsychotics less often discontinued antidiabetic medication (HR = 0.56, 95% CI: 0.47–0.66) and antihypertensives (HR = 0.63, 95% CI: 0.56–0.71)32.

Unnatural deaths, which comprises suicide, homicide, and accidents, account for 20–25% of the total number of deaths in patients with schizophrenia33. In our study, we found that the percentage of unnatural deaths stands at 20.30% of all death cases with the majority of deaths due to suicides. Studies report that antipsychotic use has a significant protective effect against suicide-related mortality34.

Disparities between people with schizophrenia and the general population have been repeatedly reported in terms of lack of medical care and screening procedures for cancer and cardiovascular diseases35,36. Various findings from the aforementioned studies indicate that patients with psychiatric disorders are receiving suboptimal care. To date, there is evidence that people with schizophrenia may encounter stigma. One research study reported that a large proportion of health service staff held negative attitudes toward patients with mental illness, which may hamper the provision of care37.

Our study is subject to certain limitations. Firstly, it is important to note that this is a single-centre study, which means it may not represent the entire population of Lithuania. Our results should be interpreted with caution, as the data was collected from just one source. However, this source is the largest hospital database in Lithuania, encompassing the most hospitalisations per year. There is a significant possibility that our study may overestimate mortality rates, and the actual situation for all individuals with schizophrenia could be more favourable. Nevertheless, it remains the only and most comprehensive study with the longest follow-up period ever conducted in Lithuania to date. Secondly, as the number of autopsies are low and continuously decreasing (in 2022, 12.2% of all deceased in Lithuania underwent an autopsy compared to 14.9% in 201838) the accuracy of cause of death data can be highly influenced by the quality of the medical records and documentation. In some cases, the cause of death may not be definitively established, because some diseases or conditions may be closely related, complicating the assignment of a single cause of death. This can result in variation in data accuracy. Thirdly, in this study, we were unfortunately unable to investigate lifestyle factors, which could improve the interpretation of the results.

Conclusions

Despite the increasing public health interventions and improvements in the management of chronic diseases, it is well recognised that patients with schizophrenia do not fully benefit from the health strategies that have led to reduced mortality in the general population. To close the mortality gap, smoking and alcohol cessation interventions, cardiovascular and cancer screening and monitoring, early diagnosis, and interventions for detected physical diseases should be regarded as imperative. We believe that a larger number of studies on causative mortality risk factors with schizophrenia are necessary to improve the devastating mortality results.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

The evolution and maintenance of trioecy with cytoplasmic male sterility

Trioecy, the co-existence of females, males and hermaphrodites, is a rare sexual system in plants that may be an intermediate state in transitions between hermaphroditism and dioecy. Previous models have identified pollen limitation as a necessary condition for the evolution of trioecy from hermaphroditism. In these models, the seed-production and pollen production of females and males relative to those of hermaphrodites, respectively, are compromised by self-fertilization by hermaphrodites under pollen- limitation. Here, we investigate the evolution of trioecy via the invasion of cytoplasmic male sterility (CMS) into androdioecious populations in which hermaphrodites co-occur with males and where the male determiner is linked to a (partial) fertility restorer. We show that the presence of males in a population renders invasion by CMS more difficult. However, the presence of males also facilitates the maintenance of trioecy even in the absence of pollen limitation by negative frequency-dependent selection, because males reduce the transmission of CMS by females by siring sons (which cannot transmit CMS). We discuss our results in light of empirical observations of trioecy in plants and its potential role in the evolution of dioecy.

Longitudinal trends in schizophrenia among older adults: a 12-year analysis of prevalence and healthcare utilization in South Korea

As populations age worldwide, it is essential to explore the changing landscape of schizophrenia across different age groups. We analyzed cases of schizophrenia reported over a 12-year period (2010–2021) using the Health Insurance Review and Assessment (HIRA) database of South Korea. We explored changes in the prevalence of schizophrenia, physical comorbidity burden, and healthcare utilization by age. The annual disease prevalence and hospitalization patterns were analyzed using linear regression and linear mixed models. Of 420,203 patients diagnosed with schizophrenia, the number and proportion of older adults (aged ≥ 50 years) significantly increased from 82,556 (0.51%) in 2010 to 188,359 (0.89%) in 2021 (p < 0.001), more rapidly than did those of younger adults. The proportion of older adults increased from 37.0% to 54.7% during this period (p < 0.001); by 2021, 44.9% were medical aid beneficiaries. Lengths of psychiatric hospitalization for older adults increased from 230.2 days to 251.8 days (p = 0.023), significantly greater than for younger adults (p < 0.001), and the use of tertiary/general hospitals decreased over time from 15.2% to 9.5% (p < 0.001) while that of hospitals/nursing homes increased from 76.9% to 88.5% (p < 0.001). Older adults consistently showed significantly higher Charlson Comorbidity Index scores (p < 0.001) and longer lengths of non-psychiatric hospitalization (p < 0.001) than younger adults. These findings highlight the distinct healthcare needs and increasing physical health burden of older adults with schizophrenia.

Responses

Your email address will not be published. Required fields are marked *